Flexion Therapeutics is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis.
We embrace a philosophy of scientific entrepreneurship which spurs innovation and empowers and inspires our people to discover, develop and commercialize transformative therapies which can make a meaningful difference in the lives of patients.
Flexion was co-founded in 2007 by Michael Clayman, M.D., and Neil Bodick, M.D., Ph.D., who leveraged the extensive drug development expertise they gained over decades at Eli Lilly and Company.
The company’s executive committee is comprised of industry veterans with deep knowledge, vast experience and the diverse leadership skills required in the biopharma industry.
